Medical network - July 11, since this year, as of July 9, national food drug safety administration released a total of 10 times the 384 Chinese medicine yinpian unqualified batch announcement; At the same time, it is understood that in addition to the sig pharmaceutical, tongrentang giants had to carry out the layout of Chinese traditional medicine, the pharmaceutical industry other listed companies have launched enclosure.
▍ fly inspection was intensified
On July 6,, according to the state food and drug safety administration issued by the food and drug verification research institute of China inspection, labeled yuan force pharmaceutical co., LTD., jilin province, anhui best wo tong Chinese medicine yinpian co., LTD., shaoyang shennong medicine technology development co., LTD., chongqing condi pharmaceutical co., LTD., and other enterprises producing 9 batches of goose not herbivorous is unqualified, unqualified project for impurities; Labeled bozhou in anhui and zhejiang and anhui Chinese medicine yinpian co., LTD., the production of 1 batch boat-fruited sterculia is unqualified, unqualified project for aflatoxin; Labeled guangxi Zhang Yitang Chinese medicine yinpian co., LTD. Production of the 2 batches of astragalus membranaceus is unqualified, unqualified project for character.
National food administration of drug safety, the above is not qualified Chinese medicine yinpian, the relevant provinces, autonomous regions and municipalities directly under the food and drug administration has taken seized seized control measures, such as requiring companies to suspend sales use, recalls, and rectification.
Requirements of administration of the state food and drug supervision and administration of production enterprise is located provinces (autonomous regions and municipalities) food and drug administration for the enterprise according to the relevant laws and regulations for production and sales of unqualified drugs illegal behavior to carry on the investigation of public three months for production and sales of unqualified drugs processing result of relevant enterprises or units, and timely report the relevant situations.
Chinese medicine yinpian quality has been one of the focus of social attention, in the past two years, the national stepped up in the link of traditional Chinese medicine and Chinese medicine yinpian flying inspection.
According to the reporter, Chinese medicine yinpian unqualified reasons include sulfur dioxide residue, not volatile matter and check under acid insoluble ash content, total ash, etc.
According to the reporter, in the past by the national food administration of drug safety production company of Chinese medicine yinpian, named some of the well-known enterprises, including yunnan baiyao, etc.
▍ Chinese medicine yinpian usher in a golden development?
However, in the country while stepping up efforts in supervising the Chinese medicine yinpian, Chinese medicine yinpian is also considered the "golden development".
"National intensify fly inspection, the market gradually standardized. However, less quality product supply, the price also will be relatively improve." An industry told reporters that quality will become a big trend. In addition, dividend policy will also promote the development of Chinese medicine yinpian grow.
In August 2016, "" much starker choices-and graver consequences-in planning development of Chinese medicine, Chinese medicine industry for the first time included in the national economic backbone industries. On July 1, 2017, the act of traditional Chinese medicine, landing the method helps to boost the development of TCM industry.
In addition, as the national health reform gradually, Chinese medicine yinpian market is expected to open.
Have learned, in May 2015, issued by the general office of the state council "about city public hospital comprehensive reform pilot guidance", pilot cities all public hospitals to promote medical apart, actively explore a variety of effective ways to reform to medicine medical mechanism, cancel the drug addition (except traditional Chinese medicine yinpian), the 2017 pilot cities to public hospital medicine proportion (not including Chinese medicine yinpian) overall to around 30%.
This means that whether cancel the drug addition or reduce the medicine proportion, Chinese medicine yinpian is beyond the scope of policy implications.
From wide card hang seng analysis according to the report, carried out with zero bonus policy, hospital of traditional Chinese medicine yinpian usage will be increased significantly.
Chinese medicine yinpian market size of 195.6 billion yuan in 2016, 2017, Chinese medicine yinpian overall size of the market is expected to reach 233 billion yuan, up 19% from a year earlier. In 2018, Chinese medicine yinpian overall market size is 273.4 billion yuan, up 17% from a year earlier.
However, in the third-party medical service platform MaiSiKang lai founder Shi Lichen view, to think that Chinese medicine yinpian industry performance is of inflection point.
"For now, Chinese medicine yinpian hospitals and clinics are the main sales channels, however, most of 3 armour hospital western medicine is more, the actual out of traditional Chinese medicine yinpian prescription is not many, in addition, most of the traditional Chinese poor earnings". Chinese medicine yinpian overall small industry scale, policy environment and sales structure without substantial change, sales volume to rise sharply.
Chinese medicine yinpian ▍ listed companies to accelerate the layout
Analysts believe that countries pay more and more attention to the development of industry of Chinese medicine, so the regulation of Chinese medicine yinpian industry is becoming more and more big.
In recent years, Chinese medicine yinpian quality HeiBang repeatedly. In the future, under the policy of national regulation continue to tighten, some less competitive small businesses will be eliminated, further improve the industry concentration.
It is understood that in addition to the sig pharmaceutical, tongrentang giants had to carry out the layout of Chinese traditional medicine, the pharmaceutical industry other listed companies have launched enclosure.
This year on June 27, temmoku pharmaceutical industry, according to the announcement in 360 million yuan to buy sun GeDeZhou, Johnson pharmaceutical 100% of total shares held, Johnson pharmaceutical company main business for the production and sales, Chinese medicine yinpian Johnson pharmaceutical production line in the production of GMP certification in 2015 and 2015 respectively. GeDeZhou as a promise performance compensation obligor, Johnson pharmaceutical industry in 2017, 2018 and 2019 audited net profit after deducting non-recurring gains and losses are not less than 39.5 million yuan, 44.2 million yuan, 48.6 million yuan.
On 17 January this year, rui kang pharmaceutical proposed a-share listed company to the price of 5.28 yuan/share subscription of new three board wellspring medical listed company issued 20.82 million shares. Well springs of traditional Chinese medicine (TCM) is a company engaged in production and sales of Chinese medicine yinpian, the raise funds of 110 million yuan, of which 39.9572 million yuan to pay for the annual output of 10000 tons of Chinese medicine yinpian, extract, Chinese medicine health project "decoration and supporting facilities.
Late last year, the new pharmaceutical issued on the acquisition of tianjin traditional Chinese medicine yinpian co., LTD. 100% stake in the equity transfer agreement and the announcement of related party transactions, the new pharmaceutical industry, said the company development strategy of "relying on the traditional Chinese medicine (TCM) core business up downstream extension, around main industry to expand the field, do real long industrial chain". Chinese medicine yinpian industry is one of the three pillars, traditional Chinese medicine industry in the industrial chain plays an important role, which forms a connecting link between the preceding and the transaction in accordance with the company's strategic development. |
